HIV-infected patients administered long-term ritonavir-boosted protease inhibitors (PIs) are at a greater risk for developing cardiovascular diseases. Endothelial dysfunction is an initiating event in HIV-associated atherosclerosis. Cultured endothelial cells can be used as a model to compare the endothelial toxicity of different PIs.
Methods
We compared the effect of darunavir (DRV), darunavir/ritonavir (DRV/r), lopinavir/ritonavir (LPV/r) and atazanavir/ritonavir (ATV/r), used at clinically relevant concentrations, on human coronary artery endothelial cell vascular function, oxidative stress, inflammation and senescence, and studied the effect of pravastatin on PI-induced alterations.
Results
Vascular endothelial cell function, evaluated by the expression of endothelial nitric oxide synthase and the production of nitric oxide and endothelin-1, was unaffected by DRV or DRV/r, but altered by LPV/r or ATV/r. DRV or DRV/r did not alter, or mildly induced oxidative stress and inflammation (phosphorylation of p65/RelA-NFκB, secretion of IL-6 and IL-8), while ATV/r and LPV/r induced a marked increase. Secretion of sICAM or sVCAM, indicative of altered cell integrity, was not or weakly altered by DRV or DRV/r, but increased by 2–3-fold by LPV/r or ATV/r. Similar results were observed regarding senescence markers: SA-β-galactosidase activation and overexpression of phospho-p53, p16ink4, p21WAF-1 and prelamin A. Pravastatin could, in part, reverse PI-induced adverse effects.
Conclusions
Ritonavir-boosted PIs differentially induced vascular endothelial cell dysfunction, reactive oxygen species production, inflammation and senescence with no effect or a mild effect of DRV/r, an intermediate effect of ATV/r, and a stronger effect of LPV/r. Statins could, in part, protect the cells from PI-induced endothelial dysfunction.
References
1.
IslamF.M., WuJ., JanssonJ., WilsonD.P.Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med2012; 13: 453–468.
2.
BavingerC., BendavidE., NiehausK.Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS ONE2013; 8: e59551.
3.
BoccaraF., LangS., MeulemanC.HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol2013; 61: 511–523.
4.
LangS., Mary-KrauseM., CotteL.Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS2010; 24: 1228–1230.
5.
WormS.W., SabinC., WeberR.Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis2010; 201: 318–330.
6.
MonforteA., ReissP., RyomL.Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS2013; 27: 407–415.
7.
PodzamczerD., Andrade-VillanuevaJ., ClotetB.Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Med2011; 12: 374–382.
8.
MenzaghiB., RicciE., CarenziL.Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). Biomed Pharmacother2013; 67: 293–298.
9.
ArathoonE., SchneiderS., BaraldiE.Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int J STD AIDS2013; 24: 12–17.
10.
OrkinC., DeJesusE., KhanlouH.Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med2013; 14: 49–59.
11.
OlivieroU., BonadiesG., ApuzziV.Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis2009; 204: 586–589.
12.
FialaM., MurphyT., MacDougallJ.HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol2004; 4: 327–337.
13.
BaligaR.S., LiuC., HoytD.G., ChavesA.A., BauerJ.A.Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol2004; 4: 199–206.
14.
LangS., Mary-KrauseM., CotteL.Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med2010; 170: 1228–1238.
15.
AbergJ.A.Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr2009; 50: 54–64.
16.
TomakaF., LefebvreE., SekarV.Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med2009; 10: 318–327.
17.
MallonP W.. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Curr Opin HIV AIDS2007; 2: 282–292.
WangX., ChaiH., YaoQ., ChenC.Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr2007; 44: 493–499.
20.
JiangB., HebertV.Y., ZaveczJ.H., DugasT.R.Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr2006; 42: 391–395.
21.
ChaiH., YangH., YanS.Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr2005; 40: 12–19.
22.
ZhongD.S., LuX.H., ConklinB.S.HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol2002; 22: 1560–1566.
23.
DavignonJ., GanzP.Role of endothelial dysfunction in atherosclerosis. Circulation2004; 109: III27–III32.
MondalD., PradhanL., AliM., AgrawalK.C.HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol2004; 4: 287–302.
26.
WangX., ChaiH., LinP.H., YaoQ., ChenC.Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol2009; 174: 771–781.
27.
FuW., ChaiH., YaoQ., ChenC.Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr2005; 39: 152–158.
28.
ConklinB.S., FuW., LinP.H.HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res2004; 63: 168–175.
29.
LefèvreC., AuclairM., BoccaraF.Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol2010; 30: 2611–2620.
30.
DubéM.P., ShenC., GreenwaldM., MatherK.J.No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis2008; 47: 567–574.
31.
GrubbJ.R., DejamA., VoellJ.Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects. J Infect Dis2006; 193: 1516–1519.
32.
MurphyR.L., BerzinsB., ZalaC.Change to atazanavir/ ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS2010; 24: 885–890.
CaronM., AuclairM., DonadilleB.Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ2007; 14: 1759–1767.
DonatoA.J., EskurzaI., SilverA.E.Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ Res2007; 100: 1659–1666.
37.
MinaminoT., MiyauchiH., YoshidaT., TatenoK., KomuroI.The role of vascular cell senescence in atherosclerosis: antisenescence as a novel therapeutic strategy for vascular aging. Curr Vasc Pharmacol2004; 2: 141–148.
38.
RagnauthC.D., WarrenD.T., LiuY.Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation2010; 121: 2200–2210.
39.
CapellB.C., CollinsF.S., NabelE.G.Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res2007; 101: 13–26.
40.
VargaR., ErikssonM., ErdosM.R.Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A2006; 103: 3250–3255.
41.
McClintockD., GordonL.B., DjabaliK.Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. Proc Natl Acad Sci U S A2006; 103: 2154–2159.
42.
CaronM., AuclairM., SterlingotH., KornprobstM., CapeauJ.Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS2003; 17: 2437–2444.
43.
CoffinierC., HudonS.E., FarberE.A.HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A2007; 104: 13432–13437.
44.
SinenskyM., FantleK., TrujilloM.The processing pathway of prelamin A. J Cell Sci1994; 107: 61–67.
45.
De JesusE., OrtizA.M., KhanlouU.Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV-treatment-naive HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211).47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17–20 September 2007, Chicago, IL, USA. Abstract H718B.
46.
TaburetA.M., RaguinG., Le TiecC.Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther2004; 75: 310–323.
47.
TaburetA.M., PikettyC., ChazallonC.Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother2004; 48: 2091–2096.
48.
SasakiC.Y., BarberiT.J., GhoshP., LongoD.L.Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem2005; 280: 34538–34547.
CapelE., AuclairM., Caron-DebarleM., CapeauJ.Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes. Antivir Ther2012; 17: 549–556.
51.
HebertV.Y., CrenshawB.L., RomanoffR.L., EkshyyanV.P., DugasT.R.Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol2004; 4: 117–131.
52.
JamaluddinM.S., LinP.H., YaoQ., ChenC.Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis2010; 208: 104–111.
53.
Hernandez-VallejoS.J., BeaupereC., LargheroJ., CapeauJ., LagathuC.HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell2013; 12: 955–965.
54.
CoffinierC., HudonS.E., LeeR.A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem2008; 283: 9797–9804.
55.
InoguchiT., SasakiS., KobayashiK., TakayanagiR., YamadaT.Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA2007; 298: 1398–1400.
56.
LiaoJ.K.Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol2002; 86: 5–18.
57.
PatelT.N., ShishehborM.H., BhattD.L.A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J2007; 28: 664–672.
58.
Caron-DebarleM., LagathuC., BoccaraF., VigourouxC., CapeauJ.HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med2010; 16: 218–229.
